He Designed Drugs to Save His Children. Now He's Working to Save Biotech, Too. - WSJ - The Wall Street Journal
wsj.comSubmitted by thewallstreetjournal7221 in business
John Crowley will become a top lobbyist for the industry as it confronts investor skepticism and regulatory challenges